Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

NCT07171827 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Anti-CD30
Brentuximab
Doxorubicin
Vinblastine
Dacarbazine
Frontline
Advanced Classical Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine
DRUG: Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine

Sponsor

Helwan University